2024International Journal of Paediatrics and GeriatricsOpen access

Use of eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia

Md. Abdul Wohab, Md. Belayet Hossain, Nilufar Akhter Banu Choudhury, Umme Nusrat Ara

Open full text 0 citations

Abstract

Eltrombopag has been used in Immune Thrombocytopenic Purpura (ITP) and also found effective in Aplastic Anemia (AA) recently. We prospectively analyzed 50 patients at Dhaka Shishu Hospital in Dhaka from January 2019 to December 2023. We included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Open-access reader

About this research paper

What this paper is about

Eltrombopag has been used in Immune Thrombocytopenic Purpura (ITP) and also found effective in Aplastic Anemia (AA) recently. We prospectively analyzed 50 patients at Dhaka Shishu Hospital in Dhaka from January 2019 to December 2023. We included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Eltrombopag has been used in Immune Thrombocytopenic Purpura (ITP) and also found effective in Aplastic Anemia (AA) recently. We prospectively analyzed 50 patients at Dhaka Shishu Hospital in Dhaka from January 2019 to December 2023. We included patients with severe AA who were refractory to at least one course of immunosuppressive therapy and persistent/chronic ITP who have received at least one previous treatment for ITP. Responses to Eltrombopag in our population were comparable to real-world experiences while tolerable hepatotoxicity and GI issues were notable. We found Eltrombopag to be a safe and efficacious agent for treating patients with ITP and AA.

Key concepts: Eltrombopag, Aplastic anemia, Immune thrombocytopenia, Medicine, Immunology, Antibody, Bone marrow

Related papers

Back to paper searchBrowse research topicsOriginal source
Use of eltrombopag in immune thrombocytopenia and acquired idiopathic aplastic anemia — Research Paper | ScholarLens